PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Columna acquires majority stake in French medtech Physidia

Columna Capital, a pan-European private equity investor, has completed a significant investment in Physidia SAS, a French specialist in home haemodialysis solutions. Existing shareholders, the Plowiecki family and founders Cyril Balas and Michel Houdou, will remain as minority shareholders.

Columna Capital (Columna), a pan-European private equity investor, has completed a significant investment in Physidia SAS (Physidia), a French specialist in home haemodialysis solutions. Existing shareholders, the Plowiecki family and founders Cyril Balas and Michel Houdou, will remain as minority shareholders.

The deal is Columna’s fourth investment from its Fund III.
 
Physidia provides mobile haemodialysis solutions for the fast-growing home care market. The Physidia S3 monitor is one of the most compact, mobile and user-friendly dialysis monitors in the world and is currently commercialised across 16 markets in EMEA. Since inception, close to one million dialysis sessions were successfully completed on the S3 within a home setting.
 
Bryan, Garnier & Co served as the exclusive financial advisor and DLA Piper/Stance Avocats as co-legal advisors to Physidia.
 
GATE Avocats served as legal advisor and PwC, Germain Maureau and Voisin Consulting as buyside due diligence providers to Columna Capital.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured